Trial Profile
A randomized, single-blind, placebo-controlled, parallel-group study evaluating the anti-inflammatory activity of GSK315234 in synovial biopsy tissue obtained from subjects with rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 315234 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 28 Jun 2012 Additional trial location (Belgium) added as reported by European Clinical Trials Database record.
- 28 Jun 2012 Planned end date changed from 16 Dec 2011 to 16 Sep 2011 as reported by European Clinical Trials Database record.
- 15 Jun 2011 New trial record